Hacker News new | past | comments | ask | show | jobs | submit
For once, this isn’t hyperbole. Metastatic pancreatic cancer hasn’t had a meaningful new treatment in literally decades - it’s been brutal chemotherapy or slightly less brutal chemotherapy.

The new generation of KRAS inhibitors, of which daraxonrasib is just the first to make it to approval, is genuinely a practice-changing breakthrough.

It won’t cure people with metastatic disease, but it will help a lot live better lives for longer.

> For once, this isn’t hyperbole.

Am I missing something?

From other sources:

> Median overall survival: 13.2 months versus about 6.6 to 6.7 months with chemotherapy.

loading story #50593274
loading story #50593308
loading story #50593356